A detailed history of Wellington Management Group LLP transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 96,294 shares of ARCT stock, worth $1.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
96,294
Previous 360,749 73.31%
Holding current value
$1.49 Million
Previous $8.78 Million 74.57%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$18.08 - $25.38 $4.78 Million - $6.71 Million
-264,455 Reduced 73.31%
96,294 $2.23 Million
Q2 2024

Aug 13, 2024

BUY
$24.35 - $44.39 $1.84 Million - $3.36 Million
75,634 Added 26.53%
360,749 $8.78 Million
Q1 2024

May 15, 2024

BUY
$31.23 - $42.99 $8.9 Million - $12.3 Million
285,115 New
285,115 $9.63 Million
Q4 2023

Feb 12, 2024

BUY
$17.71 - $32.97 $1.08 Million - $2.01 Million
60,841 New
60,841 $1.92 Million
Q3 2023

Nov 14, 2023

BUY
$25.44 - $37.35 $27,933 - $41,010
1,098 Added 2.6%
43,350 $1.11 Million
Q2 2023

Aug 14, 2023

SELL
$23.94 - $32.36 $38,495 - $52,034
-1,608 Reduced 3.67%
42,252 $1.21 Million
Q1 2023

May 12, 2023

SELL
$14.72 - $23.97 $1,692 - $2,756
-115 Reduced 0.26%
43,860 $1.05 Million
Q4 2022

Feb 13, 2023

SELL
$14.14 - $23.06 $3,520 - $5,741
-249 Reduced 0.56%
43,975 $745,000
Q3 2022

Nov 14, 2022

SELL
$13.05 - $22.13 $158,218 - $268,304
-12,124 Reduced 21.52%
44,224 $655,000
Q2 2022

Aug 15, 2022

BUY
$12.26 - $31.17 $919 - $2,337
75 Added 0.13%
56,348 $887,000
Q1 2022

May 16, 2022

BUY
$17.64 - $39.57 $96,720 - $216,962
5,483 Added 10.8%
56,273 $1.52 Million
Q4 2021

Feb 11, 2022

BUY
$34.2 - $47.56 $1.74 Million - $2.42 Million
50,790 New
50,790 $1.88 Million

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $411M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.